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ABSTRACT
Objectives: In this phase I safety trial of tenofovir gel, a candidate vaginal microbicide for
human immunodeficiency virus (HIV) prevention, a mixed-methods design was used to gather
acceptability data among women participants. The impact of acceptability factors on use of
the gel and the relationship between qualitative and quantitative acceptability data are ex-
plored.
Methods: Participants included low-risk, HIV-uninfected, and clinically stable HIV-infected
women. Participants were enrolled into cohorts stratified by HIV serostatus, sexual activity,
gel concentration, and frequency of use. Quantitative data were collected via interviewer-ad-
ministered structured questionnaires. Qualitative data were collected via semistructured small
group discussions.
Results: Although 94% of participants stated they would “probably” or “definitely” use
tenofovir gel, a range of responses emerged on multiple domains relevant to microbicide ac-
ceptability during the qualitative discussions. Lubrication, leakage, sexual pleasure, and the
possibility of covert use were central to women’s qualitative assessments of tenofovir gel.
Conclusions: Quantitative results indicate that tenofovir vaginal gel was acceptable to al-
most all users, while qualitative findings indicate that acceptability is complex, varies 
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INTRODUCTION
THE GLOBAL HIV EPIDEMIC increasingly affectswomen.1 For most, the only risk factor for be-
coming infected is the behavior of their male sex-
ual partners.1 Condoms often are unacceptable
and insufficiently used,2–4 gender-based power
imbalances can make them difficult to negoti-
ate,4–7 and religious beliefs, fertility needs, fear of
implied infidelity, and preferences for sex with-
out a barrier are challenges to their acceptability
and use. Women-initiated HIV prevention meth-
ods are urgently needed, making the develop-
ment of vaginal microbicides that reduce the like-
lihood of sexual transmission of HIV a major
public health priority.
First-generation vaginal microbicides will most
likely be topical gels inserted into the vagina with
an applicator. A variety of microbicides is cur-
rently under development, and six have entered
late-stage clinical trials.8–12 Initial product accept-
ability has been assessed in clinical trials,13–16 sur-
veys of product attributes among potential
users17,18 and their partners,19 and studies that use
over-the-counter (OTC) surrogates or placebo gel
with presumed similar formulation and applica-
tion characteristics as eventual products.20–23 Ac-
ceptability assessments in early clinical trials are
especially important because their findings can in-
fluence further development of the product.
Here, we report on acceptability data among
women participating in a phase I trial of tenofovir
gel, a candidate microbicide that inhibits HIV re-
verse transcriptase. Details of the trial are re-
ported elsewhere,24 as is acceptability among
male partners of trial participants.25 This was the
first human trial of a topical antiretroviral that
specifically inhibits a necessary replication step
in the HIV life cycle. Interest in this approach to
HIV prevention has increased in recent years
since efficacy trials of a topical surfactant
(nonoxynyl-9) and a nonspecific inhibitor of HIV
binding (cellulose sulfate) indicated that these
two types of compounds were not protective and
potentially increased HIV transmission in women
who had frequent sexual exposures to HIV. Sev-
eral larger-scale, expanded safety and proof-of-
concept trials of tenofovir gel are now underway,
based in part on the safety, tolerability, and ac-
ceptability of this microbicide demonstrated in
the study described in this paper.
MATERIALS AND METHODS
Study design and protocol
HIV Prevention Trials Network 050 (HPTN)
was a multisite, phase I, open-label, dose and fre-
quency study of 0.3% and 1.0% tenofovir vaginal
gel.24 The primary study objectives were to assess
safety, toxicity, and absorption of the product
used vaginally by women at low risk for HIV in-
fection and by HIV-infected women. The safety
study found that adverse events tended to be
mild and self-limited.24 A secondary objective of
the study was to assess product acceptability us-
ing both quantitative and qualitative methods,
which is reported here.
Cohorts were stratified by HIV serostatus and
by sexual abstinence or activity (Table 1). Partici-
pants were recruited in three U.S. cities, New York,
Philadelphia, and Providence, through community
educational activities, advertisements, and word of
mouth. Eligibility criteria included being 18–45
years of age and having regular menstrual cycles
or being amenorrheic as a result of long-acting hor-
monal therapy, that is, progestins, such as Norplant
(Wyeth-Ayerst, Philadelphia, PA). Sexually active
women had to be in a mutually monogamous het-
erosexual relationship and have vaginal sex at least
twice per week. Abstinent women refrained from
having sex from 48 hours prior to the study en-
rollment visit until the day 14 follow-up visit. All
participants underwent a consent process that was
approved by local institutional review boards. Par-
ticipants were reimbursed for study visits as fol-
lows: $50 for each visit when they had a pelvic ex-
amination (e.g., screening visit, day 2–3 visit, and
day 7 visit), $100 for each visit when they had a
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among users, and is likely shaped by a variety of contextual factors that manufacturers will
need to consider to optimize use-effectiveness. Because of the differences in the qualitative
and quantitative responses, the authors argue that future trials of candidate microbicides
should include strategic collection of mixed-methods microbicide acceptability data.
colposcopy (e.g., enrollment visit and day 14 visit),
and $25 for participation in the group interview.
Additional inclusion/exclusion criteria are de-
scribed elsewhere.24
Study product and administration
Tenofovir gel is a clear, transparent, and vis-
cous gel prepackaged in single-dose tubes. Par-
ticipants screwed the tube of product onto a poly-
ethylene applicator, filled the applicator, and
then inserted the gel; the applicator was disposed
of after use. Women used the gel for 14 days be-
tween menstrual periods, either once or twice
daily. Those assigned to once-daily dosing in-
serted the product at bedtime; those assigned to
twice-daily dosing inserted it in the morning as
well as at bedtime. Sexually active participants
replaced one of those doses with one inserted not
more than 2 hours before vaginal intercourse, at
least 2 days a week. Adherence was assessed by
an interviewer-administered questionnaire, and
nonadherence was defined as 3 or more days of
missed product use.24
Acceptability data collection and analysis
Acceptability data were collected using both
qualitative and quantitative methodologies to (1)
describe the range of user experiences, (2) explore
the impact those experiences might have for wo-
men in future trials and on use of the product
once approved, and (3) examine the utility of
mixed-method acceptability studies in microbi-
cide clinical trials. In this mixed-method design,
the qualitative data component was conducted as
a follow-up to the quantitative acceptability as-
sessment to help interpret the quantitative results
and provide additional contextual acceptability
data. A mixed-method design of this type has the
specific benefit of providing insights that cannot
be gathered from the quantitative data alone.26
The presentation of results deliberately mimics
this methodology: quantitative data on a topic are
presented first, followed by context and inter-
pretations gathered from the qualitative data. No
trends were noted within the quantitative data
based on specific demographic characteristics.
In addition to trial-related experiences, accept-
ability assessment elicited women’s thoughts
about product acceptability in real life. Although
responses about intentions for future use were
limited by the context of a clinical trial protocol,
they are also grounded in the attributes of, and
user experiences with, an actual product and pro-
vide significant insight into the factors that affect
eventual product acceptability and use.
Quantitative data
After completing the period of gel use in the
study, women completed a quantitative accept-
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TABLE 1. HPTN 050 COHORT PROGRESSION AND DATA COLLECTION
Completed Participated in
acceptability small group
Enrolled in assessment discussion
cohort (quantitative) (qualitative)
n  84 n  79 n  40a
A1 Sexually abstinent, HIV-uninfected, 12 12 0
0.3% tenofovir gel, once dailyb
A2 Sexually abstinent, HIV-uninfected, 12 11 4
1.0% tenofovir gel, once daily
A3 Sexually abstinent, HIV-uninfected, 12 11 5
0.3% tenofovir gel, twice daily
A4 Sexually abstinent, HIV-uninfected, 12 12 11
1.0% tenofovir gel, twice daily
Bc Sexually active, HIV-uninfected, HPDFd 12 11 5
C Sexually abstinent, HIV-infected, HPDF 12 12 9
Dc Sexually active, HIV-infected, HPDF 12 10 6
aSmall group discussions included 11 sexually active women, of whom 6 were HIV infected and 5 were uninfected,
and 29 abstinent women, of whom 9 were HIV infected and 20 were uninfected.
bOnce-daily applications occurred at bedtime; twice-daily applications in the morning and at bedtime. Sexually
active participants inserted gel up to 2 hours prior to intercourse in lieu of one of the other doses.
cMale partners also enrolled; see Carballo-Diéguez et al.25
dHPDF, highest practical dose and frequency: 1.0% tenofovir gel twice daily.
ability assessment where they were asked to rate
vehicle-associated factors (e.g., color, smell, con-
sistency), experiences during sex (e.g., effect on
sexual pleasure, leakage, dryness, stickiness, wet-
ness), overall likes and dislikes, likelihood of fu-
ture use, desire for a microbicide that could be
used covertly, and whether they would use it
with or without a condom. All participants com-
pleted questionnaires independently from their
male partners. Global acceptability was defined
as the proportion of participants indicating they
would probably or definitely use the product if
it were available and they had reason to be wor-
ried about risk of HIV. 
Qualitative data
Qualitative data were collected via small group
discussions. Study protocol required that discus-
sions be limited to a minimum of 2 participants
to preclude individual interviews and standard-
ize qualitative data collection. Fifteen small
groups of between 2 and 5 participants were con-
ducted with a total of 40 women. Discussions ex-
plored women’s experiences applying the gel on
a daily basis and, for those in the sexually active
cohorts, having intercourse while using the gel.
A detailed topic guide was used and covered
daily use in nonsexual contexts (e.g., application
and leakage, how it felt to use the product, per-
sonal hygiene during product use). Sexually ac-
tive participants also explored how the product
felt during sex: leakage before, during, and after;
lubricating/drying effects; and attitudes about
required condom use. Other issues included per-
ceived partner responses, attitudes regarding ve-
hicle-associated factors, potential covert use of
study product and microbicides in general, and
future likelihood of use. All discussions were au-
diotaped and subsequently transcribed.
A qualitative data-coding scheme was devel-
oped based on the topic guide, the study proto-
col, and prior acceptability research; codes were
then expanded based on content analysis of the
transcripts. Two coders, one from the collection
site and one from another site, coded each tran-
script to ensure completeness of coding. Discrep-
ancies between coders were identified, and con-
sensus was reached. The mutually agreed upon
codes were entered into the transcripts using QSR
NVivo qualitative software (QSR International
Pty Ltd., Melbourne, Australia). Data were ana-
lyzed for major themes, and relationships with
other themes and quantitative variables.
RESULTS
Participant characteristics
Eighty-four women participated in the clinical
trial. Seventy-nine participants completed quan-
titative acceptability assessments; of those, 40 also
participated in the qualitative discussions. There
were no significant demographic differences be-
tween those who completed the quantitative as-
sessment only and those who also attended the
qualitative discussions (Table 2).
Product acceptability
When asked in the quantitative assessment: “If
you had reason to be worried about getting or
passing HIV and this gel were available, how
likely would you be to use it?” 60 (76%) women
indicated they would definitely use it, 14 (18%)
indicated they would probably use it, 3 (4%) in-
dicated they would probably not use it, and 2
(3%) said they would definitely not use it. Thus,
overall, 94% said they definitely or probably
would use the product, indicating that the gel
was highly acceptable (Table 3). There were no
noteworthy differences in the quantitative ac-
ceptability results among women who partici-
pated in the qualitative discussions vs. those who
did not. The qualitative discussions, however, re-
vealed considerable variability about factors re-
lated to acceptability.
Perceptions of product and its application. A high
proportion of all women indicated on the quan-
titative assessment that they liked the gel’s color,
smell, and consistency (Table 3). During qualita-
tive discussions, participants said they perceived
the gel prior to insertion to be clear, colorless, and
odorless, qualities they often praised. For exam-
ple, one described the gel’s scent as “comfortable”
and “not strong.” Most participants found the
consistency acceptable (e.g., “just the right tex-
ture,” “not too thick, not too thin”), although
some thought a thicker consistency would im-
prove it. Most participants reported that the
product was “easy” or “very easy” to use, in part
because the application process mirrored that of
other vaginal products they had used. Some par-
ticipants reported that the application process re-
quired privacy and time—at least 5 minutes, ac-
cording to 1 participant.
Responses to daily use. Daily use leakage (as op-
posed to leakage with sex) was not measured in
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the quantitative assessment. During qualitative
discussions, however, leakage of the product af-
ter insertion was commonly reported. Several
women described the gel as “messy,” “sticky,” or
“gooey,” which they did not find acceptable. The
amount of leakage and the degree to which par-
ticipants considered it a nuisance, however, var-
ied considerably. Some indicated the leakage was
significant, like a “waterfall.” It left them feeling
“moist all the time.” A sexually abstinent partic-
ipant described leakage as being similar to when
semen drips out of her vagina after her partner
ejaculates; other women agreed. One participant
reported that leakage was greater when she was
on her feet and moving around after application
as opposed to lying down following insertion of
the product. In contrast, several indicated that
they did not find the product messy. Approxi-
mately twice as many participants identified the
product as leaking and messy than those who did
not.
Because of product leakage, several women
changed their hygiene habits by wiping more fre-
quently after urination or cleaning themselves
more thoroughly. Similarly, panty liners were
provided by study for participants’ use, and in-
dividual women responded differently to this,
with some feeling a need to change them more
frequently and others hardly needing them.
Responses to use during sex. Table 3 summarizes
quantitative data related to gel use during sex.
Most participants (90%) indicated either that the
gel increased their sexual pleasure or that it made
no difference. Similarly, most (86%) felt the prod-
uct increased their male partner’s sexual pleasure
or that it made no difference. In discussions, some
sexually active women reported leakage of gel
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TABLE 2. PATIENT DEMOGRAPHICS
Completed follow-up acceptability assessment Participated in small group discussions
(n  79) (n  40)
Latina n  15 (19%) n  10 (25%)
African American 4 3 
White 1 1 
Other 10 6 
Non-Latina n  64 (81%) n  30 (70%)
African American 31 15 
White 27 13 
Asian 2 1 
Multiraciala 2 0
Other 2 1 
Mean age 36.2 years 36.0 years
Highest level of education
Less than high school 23 (29%) 12 (30%)
High school diploma 24 (30%) 11 (28%)
Some college 17 (22%) 10 (25%)
College degree 12 (15%) 7 (18%)
Some postcollege 1 (1%) 0 
Graduate/professional degree 2 (3%) 0 
Type of student
Full-time student 6 (8%) 3 (8%)
Part-time student 7 (9%) 3 (8%)
Not a student 66 (84%) 34 (85%)
Employment status
Full-time employment 16 (20%) 6 (15%)
Part-time employment 12 (15%) 6 (15%)
Unemployed 50 (63%) 28 (70%)
Other 1 (1%) 0 
Household income
$6,000/year 16 (20%) 10 (25%)
$6,000–$11,999/year 35 (44%) 20 (50%)
$12,000–$29,999/year 17 (22%) 5 (13%)
$30,000–$59,999/year 9 (11%) 4 (10%)
$60,000/year 2 (3%) 1 (3%)
a2 participants identified themselves as having more than one ethnicity; one participant identified herself as
“American Indian Alaska native, black/African American,” another identified as “Native Hawaiian/other Pacific
Islander, French.”
during sex. Here, too, there was individual vari-
ation: some women reported leakage not much
greater than what they usually experience with
sex, and others mentioned it would not pose a
problem because they normally wash after sex.
Still others viewed the gel as making sex “messy.”
Most participants reported the gel made them feel
more lubricated during sex, although responses
to this additional lubrication varied widely. Some
said it enhanced the sexual experience: “It made
sex a little more enjoyable because it was
moister”; “We didn’t have to use extra lube be-
cause the gel already did that for us.” A few, how-
ever, reported too much lubrication, which was
not pleasurable: “this was a little more wet, and
I . . . like it drier. . . . I would’ve preferred it to be
more  . . . drier, you know?”
The amount of time that elapsed after product
application also seemed to affect how “slippery”
sex felt. One participant reported that she had sex
after the prescribed 2-hours postgel insertion win-
dow and noted that she was “not as wet as you
would be when you first put it in.” This was prefer-
able to the discomfort she had when applying the
gel closer to coitus. Finally, a few women said there
was little change in lubrication levels.
Condom use and acceptability. When asked,
“Would you use the gel alone or only with a con-
dom?” 26 (33%) of the women said they would
use the gel alone, and 53 (67%) said they would
use it only with a condom. Of the sexually active
participants, 3 (14%) said they would use the gel
alone, and 18 (86%) said they would use the gel
only with a condom. Of the 22 HIV-positive par-
ticipants, 8 (36%) said they would use the gel
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TABLE 3. RESULTS FROM FOLLOW-UP ACCEPTABILITY ASSESSMENT: QUANTITATIVE ACCEPTABILITY RESULTS BY SEXUALLY
ABSTINENT AND SEXUALLY ACTIVE PARTICIPANTS (N  79), FEMALE PARTICIPANT EXPERIENCES WHILE USING




n  58 n  21 n  79
Overall liked gel 45 (78%) 17 (81%) 62 (78%)
Liked somewhat/a lot gel’s
Color 53 (91%) 21 (100%) 74 (94%)
Smell 46 (79%) 19 (90%) 65 (82%)
Consistency 42 (72%) 17 (81%) 59 (75%)
Likelihood of useb
Definitely/probably use 55 (95%) 19 (90%) 74 (94%)
Definitely/probably not use 3 (5%) 2 (10%) 5 (6%)
Of the sexually active participants (n  22)
Did the gel Yes No
cause an interruption in sex in order to apply? 1 (5%) 21 (95%)
make sex feel more wet? 19 (86%) 3 (14%)
dry out during sex? 1 (5) 21 (95)
get sticky during sex? 5 (23) 17 (77)
leak out
before sex? 9 (41) 13 (59)
during sex? 11 (50) 11 (50)
after sex? 15 (68) 7 (32)
Strongly Agree No Disagree Strongly
agree somewhat difference somewhat disagree
n (%) n (%) n (%) n (%) n (%)
Overall, I felt that using the gel
increased my sexual pleasure 5 (23) 5 (23) 10 (45) 2 (9) 0 (0)
decreased my sexual pleasure 1 (5) 1 (5) 8 (36) 1 (5) 11 (50)
increased his sexual pleasure 6 (27) 5 (23) 8 (36) 2 (9) 1 (5)
decreased his sexual pleasure 1 (5) 3 (14) 8 (36) 3 (14) 7 (32)
aThese data come from 21 women in sexually active cohorts and from 1 woman in an abstinent cohort who report-
ed having sex while using this product.
b”If you had reason to be worried about getting or passing HIV and this gel were available, how likely would you
be to use it?”
alone, and 14 (64%) said they would use it only
with a condom. In a discussion, one participant
said, “To be on the safe side and if this is a prod-
uct to help . . . prevent HIV, I would use them
both. I would use the gel and I would use the
condom.” In the qualitative data, many condom
discussions centered on the requirement to use
them throughout the trial; this fact alone made
sex different for many participants, as only a few
reported regular condom use prior to study par-
ticipation. Many complained about using con-
doms or reported that their partners did not like
them, although some noted that the gel made con-
dom use more appealing. Some participants as-
sumed that an efficacious gel would be an alter-
native to condoms: “If my partner didn’t really
enjoy using condoms, I would still have some-
thing that I could use to protect the both of us.”
Covert use. In the quantitative assessment, 56
women (71%) said they would prefer a microbi-
cide that could not be noticed by a sex partner,
whereas 15 (19%) said it would not matter, and 8
(10%) said they would not prefer a product that
could not be noticed by a sex partner. In the dis-
cussions, women generally thought that certain
characteristics of the gel, including its lack of
color and odor, made it less likely to be noticed
by a partner. Some noted that a woman could at-
tribute additional lubrication from microbicide
use to lubricant use. At the same time, many wo-
men believed that regular partners might detect
the increase in lubrication associated with prod-
uct use: “The gel, it’s like really wet . . . if your
partner knows you . . . he will be able to tell the
difference.” Others thought that unfamiliar, or
new, partners would not detect the increased
wetness or that they could explain it if they did:
“Honestly, I could use it with a man and what he
would think was . . . ‘this girl is just wet!’ ”
Although many women indicated that, in their
own relationships, they would tell their partner
if they were using such a product, there was a
strong sense that having a product that could be
used covertly would be useful to women gener-
ally. For casual relationships, participants be-
lieved that it was the woman’s choice as to
whether or not to inform her partner of product
use. Some women suggested that there were cir-
cumstances, even in established relationships,
where it would be acceptable to use the product
covertly, including when a male partner would
not use condoms.
HIV-infected women. HIV-infected women
wanted a microbicide that protects their partners
from infection and themselves from reinfection,
saying microbicides could allay their fears about
infecting other partners. However, they also
questioned whether a microbicide would be ef-
fective for a person with “full-blown AIDS.” In-
terestingly, 1 participant attributed changes in
her viral load, in part, to product use. Such
changes are not supported by the clinical safety
data, and the woman did not experience any ma-
jor fluctuation in her plasma viral load.24
DISCUSSION
Although results indicate high acceptability of
tenofovir gel based on quantitative measures, a
wider range of product ratings emerged qualita-
tively, indicating some situations in which be-
havioral and contextual factors altered degrees of
acceptability. Whereas participants supported the
idea of a women-controlled method for HIV pre-
vention and expressed satisfaction with many
characteristics of the gel, leakage during and af-
ter sex was unacceptable for some.
Quantitative and qualitative acceptability data
were constrained, necessarily, by the study pro-
tocol, including the enrollment of more abstinent
than active participants, the requirement that
male partners of active participants wear con-
doms during vaginal intercourse, and require-
ments to refrain from oral and anal sex, use of sex
toys, and use of other vaginal products. Although
only half of the enrolled women participated in
small group discussions, there were no signifi-
cant demographic or quantitative acceptability
differences overall (e.g., likes and dislikes of gel,
leakage) between those who did and did not par-
ticipate in the qualitative discussions. 
The acceptability of tenofovir gel as a microbi-
cide will likely be closely related to its perceived
impact on sexual pleasure,27 a domain that inter-
sects strongly with product leakage and lubricat-
ing quality during sex. Themes raised during the
qualitative assessments about the interaction of
product leakage and sexual pleasure included (1)
how tolerable was leakage during or after sex, (2)
how personal preferences for sexual lubrication
interact with the product and together influence
sexual pleasure, and (3) the relationship between
lubrication and perceived partner awareness of
gel use. Similar themes are relevant to covert use,
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including relationship factors. These include how
well the partner knows the woman’s typical
physical responses during sex, as well as the sta-
tus of the relationship. For some, microbicides
may be appropriate with new or casual partners
who may not notice a difference in lubrication, a
finding supported by other qualitative investiga-
tions of microbicide acceptability.14
Messiness and leakage of the gel in relation to
daily use were important themes in the small
group discussions, and these warrant further
study. Other microbicide acceptability studies
have also noted significant product leakage, ne-
cessitating more demanding hygiene require-
ments to compensate.14,15 Phase II extended
safety and acceptability testing of both once-daily
and coitally-dependent tenofovir gel is under-
way, and further acceptability studies will sig-
nificantly advance our knowledge. To enhance
adherence to study protocols, potential partici-
pants will need to be educated to expect and man-
age these findings. It is also possible that women
may be paying increased attention to their bod-
ies as a result of trial participation and frequent
application of the product. Careful mixed-meth-
ods data collection in expanded safety and effi-
cacy trials will be important for clarifying these
issues and anticipating acceptability of tenofovir
gel. 
The perception by 1 HIV-infected participant
that the use of the gel was associated with fluc-
tuations in her viral load illustrates that user per-
ceptions of product effects, whether or not they
are clinically supported, can influence accept-
ability, a point noted in other research as well.28
This may be particularly relevant with products
like tenofovir that have antiretroviral activity.
Women’s perceptions of a microbicide’s effects
and their reasons for ascribing such effects, even
where none exist, must be understood.
The acceptability of an investigational product
will be inevitably influenced by the context of the
trial itself, including protocol requirements for
specific sexual behavior (e.g., abstinence vs. pro-
tocol-specific minimal frequency of sex) and con-
sistent male condom use in sexually active co-
horts. Because no vaginal microbicide candidate
has yet been shown to be effective, within-trial
assessments provide the only opportunity to
learn about the experiences of women and men
who have used these products. Protocol-man-
dated sexual and hygiene requirements and re-
strictions (e.g., no douching during the study)
may have influenced comfort or acceptability.
Not all protocol demands, however, limit knowl-
edge gained. There are advantages to trial-related
investigations of microbicide acceptability, in-
cluding how daily use of product during a clini-
cal trial differs from likely coitally-dependent use
in real life or how condom use influences micro-
bicide acceptability.
Because of the requirement for condom use, it
is unclear to what extent participant acceptabil-
ity ratings were independently associated with
product use vs. the combination of product and
male condom use during sex. Most participants,
however, indicated a desire to use the gel with a
condom. As condom use will be a likely recom-
mendation for first-generation microbicides,29
which are unlikely to be 100% effective, condom-
based acceptability data are highly relevant. Fur-
ther, this aspect of acceptability, which has pre-
viously been thought of as a limitation of clinical
trial data, may actually be a significant accept-
ability factor that should continue to be assessed.
Efficacy trials will invariably mandate consistent
condom use, but as they will be enrolling high-
risk women, lapses should be captured during
follow-up visits, such that microbicide use with
and without condoms can be studied in greater
detail.
A limitation of the study is that because it was
a phase I safety trial it necessarily enrolled a small
number of participants. Further, only half of those
were able to participate in qualitative groups.
This limits in-depth analysis across demographic
variables. Additionally, because of the small sam-
ple size and the enrollment criteria, these data
may not be generalizable to the broader popula-
tion of women who will most want and use a
vaginal microbicide.
One of the strengths of qualitative data collec-
tion in clinical trials is the ability to focus on the
entire process of product use, from application
through sexual activity. For example, collecting
data reflective of participants’ application learn-
ing curves, comfort with the applicator, and time
and privacy needs is a strength of acceptability
data obtained from daily use in clinical trials pre-
cisely because participants have so much experi-
ence with the application process during that
time. Participant comments that the gel made
condom use more appealing, coupled with re-
ports by the majority of participants that teno-
fovir gel increased or made no difference in their
sexual pleasure, suggest that microbicide use
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could be promoted as a way to motivate condom
use.
CONCLUSIONS
Women indicated a high likelihood of using
tenofovir gel if it were available as a microbicide
for reducing the likelihood of HIV infection. The
utility of conducting mixed-methods studies of
microbicide acceptability during clinical trials is
demonstrated by the differences between the
qualitative and quantitative data reported here.
This suggests that effective and integrated data
collection methods need to be considered early in
planning future trials and points to the impor-
tance of qualitative data for elucidating user opin-
ions about product use acceptability and likely
patterns of use. The study findings also demon-
strate a need to expand the quantitative accept-
ability assessments in order to capture more de-
tails on factors related to acceptability.
Acceptability remains a strongly subjective
construct, continually shaped by individual opin-
ions that are themselves likely to be formed by a
variety of factors, including physical well-being,
sexual pleasure, partner and relationship factors,
and other contextual and cultural norms. Future
acceptability assessments might profitably em-
ploy both quantitative and qualitative methods
but should do so in parsimonious ways most
applicable to the appropriate phase in product
development30,31 Additionally, there remains a
strong need to develop robust acceptability as-
sessment tools that can be standardized for use
across microbicide trials, allowing for increased
knowledge by creating an opportunity for meta-
analyses across studies to delineate important
themes that may increase the acceptance of new
microbicides30,31,32
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